Talha Badar: Outcome after stopping venetoclax and azacitidine
Talha Badar shared on X:
“American Journal of Hematology, Blood Research Journal, Wiley Online Library.
Outcome after stopping venetoclax and azacitidine.
28/62 ND AML patients stopped hypomethylating agent and venetoclax.
With a median follow-up of 23 months (IQR, 20–32), mOS and treatment-free survival were 44 (IQR, 16-NR) and 16 (IQR, 8–27) months, respectively MRD -ve had 2 yrs treatment free survival of 80%.
RR cohort (n = 22), mOS and treatment-free survival were 19 (IQR, 17–31) and 10 (IQR, 5-NR) months, respectively. No different in outcome between patients who only stopped venetoclax vs. venetoclax-azacitidine.”
Source: Talha Badar/X
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
Authors: Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, David A. Sallman, Justine Decroocq, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Chantal Himberlin, Pierre Peterlin, Sarah Bonnet, Onyee Chan, Jeffrey Lancet, Rami Komrokji, François Vergez, Nicolas Chapuis, Tatiana Raskovalova, Adriana Plesa, Anne-Catherine Lhoumeau, Ariane Mineur, Marie Anne Hospital, Arnaud Pigneux, Norbert Vey, and Christian Récher.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023